Craig W. Smith has played a central role in many of the firm’s significant successes on behalf of shareholders and public corporations in derivative and securities actions. His clients include individuals and institutional investors with holdings in the banking, finance and investment, biotechnology, construction, defense, for-profit education, information technology, leisure, consumer goods, and pharmaceutical industries. Mr. Smith also serves as Robbins LLP’s General Counsel. Mr. Smith has been recognized by his peers as a San Diego Super Lawyer for ten consecutive years.
Before joining Robbins LLP, Mr. Smith served for four years as division and regional counsel for UBS Financial Services, Inc., where he advised management regarding securities litigation, financial regulation, compliance and risk management. He spent the first decade of his career at O’Melveny & Myers LLP, where he defended Fortune 500 companies and professional services firms in securities fraud class actions, shareholder derivative litigation, and SEC investigations and enforcement actions, as well as professional malpractice and business tort matters. He served for five years on O’Melveny’s firm-wide Pro Bono Committee.
Mr. Smith earned his Juris Doctorate from the Yale Law School, where he externed for the U.S. Attorney’s Office in New Haven, Connecticut. Mr. Smith earned his Bachelor of Arts in Political Science from the University of California, Berkeley, where he was awarded Highest Honors in Political Science, Highest Distinction in the College of Letters and Science, and was granted early initiation into Phi Beta Kapa in his junior year.
EDUCATION
ADMISSIONS
AFFILIATIONS
Craig W. Smith was instrumental to the Robbins LLP team that acted as additional counsel to the federal plaintiffs in this coordinated litigation on behalf of Altria Group Inc. Plaintiffs alleged that Altria’s $12.8 billion investment in Juul Labs, Inc. was fundamentally troubling as it indicated that the largest tobacco company in the U.S. – a Company that claimed to be committed to youth tobacco use prevention – was willing to invest significant funds in a company whose irresponsible actions played an outsized role in capitalizing on and accelerating the youth vaping epidemic. Under Mr. Smith’s guidance, Robbins LLP was instrumental in achieving a hard-fought settlement that required multiple mediations, months of continued discussions, informal mediation conferences, and extensive document review of over 35 million pages. When achieved, the settlement contemplated a comprehensive and global resolution of the actions. The settlement requires Altria to commit to funding $117 million over five years, with a minimum spend of $20 million each year to address policy and governance measures relating to youth prevention and transaction oversight that may include: (i) positive youth development programs; (ii) smoking and vaping cessation treatment; and (iii) point of sale age verification technology.
SOUTHERN COMPANY
Mr. Smith led Robbins LLP as it served as co-lead counsel for the plaintiffs in this federal derivative action arising out of certain of Southern Company’s officers’ and directors’ breaches of fiduciary duty in connection with the Company’s attempted construction and subsequent decommissioning of the world’s first commercial-scale power plant to integrate coal gasification and carbon sequestration in Kemper County, MI, which resulted in significant financial loss. After extensive discovery and multiple mediator-facilitated settlement negotiations, Mr. Smith helped achieve a settlement that provides substantial benefits to Southern, including the implementation of significant corporate governance reforms that target the alleged lapses in Board-and management-level supervision of Large Capital Projects and reduce the likelihood the Company will suffer similar lapses in the future, which, “have the potential to contribute hundreds of millions of dollars in value to Southern over time.” In re The Southern Company Shareholder Derivative Litigation, No 1:17-CV-725-MHC (N. Dist. Of Georgia June 9, 2022)
Robbins LLP served as lead counsel in shareholder derivative litigation brought on behalf of Fifth Street Finance Corp., challenging conflicts of interest in Fifth Street’s relationship with its investment advisor, FSAM. Plaintiffs alleged that certain Fifth Street and FSAM officers and directors caused Fifth Street to make reckless investments, use bogus accounting, and pay excessive fees to inflate FSAM’s perceived value in the lead up to FSAM’s initial public offering. Mr. Smith led the settlement negotiations that resulted in advisory fee reductions worth $30 million and comprehensive corporate governance, oversight, and conflicts management enhancements. In re Fifth Street Finance Corp. Shareholder Derivative Litigation, Lead Case No. 3:15-cv-01795-RNC (D. Conn. Dec. 13, 2016).
AVON PRODUCTS, INC.
Mr. Smith and his team played a leading role in shareholder derivative litigation brought on behalf of Avon Products, Inc., against officers and directors alleged to have turned a blind eye to bribes made in violation of the Foreign Corrupt Practices Act to secure the first foreign direct sales license in China. Mr. Smith led the negotiations that resulted in Avon’s agreement to adopt a comprehensive corporate governance and compliance reform program, which The Wall Street Journal praised as “a victory for shareholders looking for accountability from the business.” Pritika v. Jung, No. 651479/2015 (N.Y. Sup. Ct. May 1, 2015).
CAREER EDUCATION CORP. (KNOW KNOWN AS PERDOCEO EDUCATION CORPORATION)
Mr. Smith played a leading role in shareholder derivative litigation brought on behalf of Career Education Corporation against officers and directors alleged to have caused its for-profit schools to falsify job placement and student loan repayment rates and to fail to meet accreditation standards, jeopardizing access to the Title IV federal student loan funds that account for the lion’s share of its revenues. Mr. Smith and his co-counsel in Alex v. McCullough, No. 1:12-cv-08834 (N.D. Ill. Dec. 5, 2012); Bangari v. Lesnik, No. 1:11-CH-41973 (Ill. Cir. Ct.-Cook Cty. Dec. 11, 2011); and Cook v. McCullough, No. 1:11-cv-09119 (N.D. Ill. Dec. 22, 2011), negotiated a global settlement that secured a $20 million recovery for Career Education, as well as comprehensive board and management-level governance and oversight reforms.
E*TRADE FINANCIAL CORPORATION
Mr. Smith negotiated a comprehensive package of enhancements to internal controls over accounting and financial reporting and board oversight of enterprise risk and stock repurchases to address allegations that massive undisclosed risk-taking and manipulative stock repurchases in violation of Section 10(b) of the Securities Exchange Act of 1934 caused the company to suffer catastrophic losses in the 2007-2010 financial crisis, and payment of over $26 million to settle the related securities class action. Professor Jeffry N. Gordon of the New York University Law School opined that “the Reforms meaningfully reduce the risk of recurrence of such a shareholder catastrophe and thus create economic value many multiples greater than the requested attorneys’ fees.” Rubery v. Caplan, et al., No. 1:07-cv-08612 (S.D.N.Y. Oct. 3, 2013).
MOTOROLA, INC.
Mr. Smith led the firm’s efforts in shareholder derivative litigation brought to address allegations that certain officers and directors of the company published misleading product development and introduction projections and caused the company to repurchase stock at artificially inflated prices in violation of Section 10(b) of the Securities Exchange Act of 1934. After the company authorized payment of $200 million to settle related securities fraud claims, Mr. Smith negotiated comprehensive financial reporting, risk management, stock repurchases, and board oversight reforms designed to prevent recurrence of these harms and restore investor confidence. In re Motorola, Inc. Derivative Litigation, Lead Case No. 07CH23297 (Ill. Cir. Ct-Cook Cty. Nov. 29, 2012).
BIO-PHARMA ACTIONS
Mr. Smith spearheaded the litigation and settlements in a number of shareholder derivative actions brought on behalf of biotechnology companies, including Geron Corporation, MannKind Corporation, and CTI BioPharma (f.k.a. Cell Therapeutics), that led to their adoption of state-of-the-art clinical trial and disclosure oversight and internal controls programs, following costly mismanagement of clinical trials and publication of misleading disclosures. Oriente v. Scarlett et al., No. CVV528121 (Cal. Super. Ct.-San Mateo Cty. April 21, 2014); In re MannKind Corp. Derivative Litigation, No. 1:11-cv-05003-GAF-SSx (C.D. Ca. June 13, 2011); In re Cell Therapeutics, Inc., Derivative Litigation, No. 2:10-cv-00564-MJP (W.D. Wash.-Seattle Apr. 1, 2010).
HECKMAN CORPORATION
Mr. Smith and his team’s litigation efforts prompted Heckmann Corporation’s Board of Directors to create a Special Litigation Committee to evaluate legal claims arising from the company’s disastrous acquisition of a China-based water company. Mr. Smith persuaded the Committee to adopt reforms designed to enhance transaction due diligence, disclose practices, and robust investigation of acquisition targets’ internal controls over accounting and financial reporting. Hess v. Heckmann et al., No. INC 10010407 (Cal. Super. Ct.-Riverside Cty. Nov. 18, 2010).
BROCADE COMMUNICATIONS SYSTEMS, INC.
Mr. Smith played a key role in persuading the Special Litigation Committee formed by Brocade’s Board to prosecute stock option backdating claims against former officers and directors. In re Brocade Communication Systems, Inc., Derivative Litigation, No. 1:05-cv-041683 (Cal. Super. Ct.-Santa Clara Cty. Jan. 28, 2010). Mr. Smith was part of the four-lawyer team that met with the Committee and convinced it to retain the firm as co-counsel and to pursue the claims. Brocade recovered tens of millions of dollars and extinguished its obligation to fund the criminal defense of its former CEO.
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.